In vivo administration of urolithin A and B prevents the occurrence of cardiac dysfunction in streptozotocin-induced diabetic rats

Table 2 Concentrations (μM) of the urolithins detected in plasma and urine samples of rats treated with UB and UA

Metabolite	D3-UA			D3-UB			p value^b
Metabolite	Median (IQR)	Min–max	Samples^a	Median (IQR)	Min–max	Samples	p value^b
Plasma
Urolithin B-sulphate	0.000 (0.003)	0.000–0.012	1/6	0.339 (3.895)	0.065–5.858	9/9	§§§
Urolithin B-glucuronide	0.019 (0.033)	0.000–0.048	5/6	0.000 (0.032)	0.000–0.064	4/9	n.s.
Urolithin A	0.005 (0.007)	0.000–0.015	5/6	n.d.			–
Urolithin A-sulphate	0.220 (0.124)	0.121–0.394	6/6	n.d.			–
Urine
Urolithin B-sulphate	n.d.			0.344 (5.622)	0.063–9.248	5/5	–

n.d. not detected (below LOD), n.s not significant
^aNumber of samples where each metabolite was quantified/detected
^b§§§ indicates p < 0.001 significant differences between D3_UA and D3_UB (Mann–Whitney U test)

ISSN: 1475-2840